BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $84,188 | -90.0% | 11,891 | -88.2% | 0.00% | -100.0% |
Q1 2023 | $842,140 | -54.9% | 100,976 | -37.9% | 0.00% | -25.0% |
Q4 2022 | $1,866,051 | +107.6% | 162,548 | +127.7% | 0.00% | +100.0% |
Q3 2022 | $899,000 | -42.0% | 71,374 | -51.3% | 0.00% | 0.0% |
Q2 2022 | $1,549,000 | -19.3% | 146,446 | +5.6% | 0.00% | 0.0% |
Q4 2021 | $1,920,000 | +14.0% | 138,644 | +18.3% | 0.00% | 0.0% |
Q3 2021 | $1,684,000 | +33.9% | 117,185 | -5.3% | 0.00% | 0.0% |
Q1 2021 | $1,258,000 | -21.8% | 123,699 | -42.7% | 0.00% | -33.3% |
Q4 2020 | $1,609,000 | +241.6% | 216,025 | +57.7% | 0.00% | +200.0% |
Q3 2020 | $471,000 | +19.8% | 136,977 | +66.0% | 0.00% | -50.0% |
Q2 2020 | $393,000 | +1968.4% | 82,525 | +1384.8% | 0.00% | – |
Q4 2019 | $19,000 | +111.1% | 5,558 | +80.2% | 0.00% | – |
Q3 2019 | $9,000 | -97.7% | 3,085 | -97.0% | 0.00% | -100.0% |
Q2 2019 | $395,000 | +1617.4% | 104,290 | +3598.2% | 0.00% | – |
Q1 2019 | $23,000 | -23.3% | 2,820 | -27.3% | 0.00% | – |
Q3 2018 | $30,000 | -28.6% | 3,879 | -46.7% | 0.00% | – |
Q2 2018 | $42,000 | +200.0% | 7,283 | +143.7% | 0.00% | – |
Q1 2018 | $14,000 | +100.0% | 2,988 | +114.3% | 0.00% | – |
Q4 2017 | $7,000 | -97.2% | 1,394 | -97.1% | 0.00% | -100.0% |
Q3 2017 | $248,000 | -69.2% | 47,367 | -50.6% | 0.00% | -77.8% |
Q1 2017 | $806,000 | +56.8% | 95,908 | +18.1% | 0.01% | +80.0% |
Q4 2016 | $514,000 | +3112.5% | 81,176 | +2084.5% | 0.01% | – |
Q3 2016 | $16,000 | -56.8% | 3,716 | -71.2% | 0.00% | – |
Q2 2016 | $37,000 | +117.6% | 12,897 | +108.8% | 0.00% | – |
Q1 2016 | $17,000 | -46.9% | 6,178 | +123.0% | 0.00% | – |
Q3 2015 | $32,000 | -63.6% | 2,770 | -71.5% | 0.00% | -100.0% |
Q1 2015 | $88,000 | -40.1% | 9,735 | -35.4% | 0.00% | -50.0% |
Q3 2014 | $147,000 | +110.0% | 15,064 | +128.3% | 0.00% | +100.0% |
Q1 2014 | $70,000 | -87.1% | 6,599 | -90.7% | 0.00% | -87.5% |
Q4 2013 | $541,000 | +113.8% | 71,125 | +104.4% | 0.01% | +60.0% |
Q3 2013 | $253,000 | +1000.0% | 34,805 | +130.2% | 0.01% | +400.0% |
Q2 2013 | $23,000 | – | 15,119 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |